The aim of this study was to evaluate the relaxant effect of resveratrol (RVT), one of the most commonly employed dietary polyphenols, in rat corpus cavernosum, and to further investigate the contribution of possible underlying mechanisms. Strips of corpus cavernosum were used in organ baths for isometric tension studies. RVT (10−6–10−4 M) produced concentration-dependent relaxation responses in rat corpus cavernosum precontracted by phenylephrine. The relaxant responses to RVT partially, but significantly inhibited by removal of endothelium. Nitric oxide (NO) synthase (NOS) blocker N-nitro-L-arginine methyl ester (L-NAME, 10−4 M) or soluble guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10−5 M) caused a significant inhibition on relaxation response to RVT, whereas cyclooxygenase inhibitor indomethacin (10−5 M) did not significantly alter relaxant responses of corpus cavernosum strips to RVT. Corpus cavernosum contractions induced by stepwise addition to Ca2+ to high KCl solution with no Ca2+ were significantly inhibited by RVT incubation. The treatment of corpus cavernosum tissues with non-specific potassium channel inhibitor tetraethylammonium (TEA, 10−2 M) did also significantly affect the relaxant activity of RVT. Otherwise, the relaxation response of corpus cavernosum induced by the phosphodiesterase-5 inhibitor sildenafil increased significantly in the group pretreated with 10−5 M RVT. These results demonstrated that RVT has a potent relaxant effect on rat corpus cavernosum via endothelium-dependent and -independent mechanisms. Endothelium-dependent relaxation of corpus cavernosum to RVT is thought to be mediated primarily through NO/cGMP signaling pathway, and possibly an additional mechanism, endothelium-dependent hyperpolarization factor (EDHF). The residual endothelium-independent corpus cavernosum relaxation induced by RVT is uncertain but seems to depend on the interactions of RVT with Ca2+ entry mechanism from the extracellular space and also other undefined direct effects in this tissue.
Your institute does not have access to this article
Subscribe to Journal
Get full journal access for 1 year
only $14.88 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Andersson KE . Pharmacology of penile erection. Pharmacol Rev 2001; 53: 417–450.
Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH . Nitric oxide: a physiologic mediator of penile erection. Science 1992; 257: 401–403.
Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ . Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90–94.
NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83–90.
Ayta IA, Mckinlay JB, Krane RJ . The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50–56.
Vlachopoulos C, Rokkas K, Ioakeimidis N, Stefanadis C . Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links. Eur Urol 2007; 52: 1590–1600.
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB . Impotence and its medical and psychosocial correlates: results of the Massachusetts maleaging study. J Urol 1994; 151: 54–61.
Corbin JD, Francis SH . Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 56: 453–459.
Jackson G, Rosen RC, Kloner RA, Kostis JB . The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 2006; 3: 28–36.
Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009; 26: 813–825.
Küthe A, Montorsi F, Andersson KE, Stief CG . Phosphodiesterase inhibitors for the treatment of erectile dysfunction. Curr Opin Investig Drugs 2002; 3: 1489–1495.
Shoji T, Akazome Y, Kanda T, Ikeda M . The toxicology and safety of apple polyphenol extract. Food Chem Toxicol 2004; 42: 959–967.
Nagasako-Akazome Y, Honma D, Tagashira M, Kanda T, Yasue M, Ohtake Y . Safety evaluation of polyphenols extracted from hop bracts. Food Chem Toxicol 2007; 45: 1383–1392.
Shen CL, Chyu MC, Pence BC, Yeh JK, Zhang Y, Felton CK et al. Green tea polyphenols supplementation and Tai Chi exercise for postmenopausal osteopenic women: safety and quality of life report. BMC Complement Altern Med 2010; 10: 76.
Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003; 9: 3312–3319.
Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010; 70: 9003–9011.
Almeida L, Vaz-da-Silva M, Falcão A, Soares E, Costa R, Loureiro AI et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 2009; 53: 7–15.
Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K . Clinical trials of resveratrol. Ann NY Acad Sci 2011; 1215: 161–169.
Jager U, Nguyen-Duong H . Relaxant effect of trans-resveratrol on isolated porcine coronary arteries. Arzneimittelforschung 1999; 49: 207–211.
Das DK, Maulik N . Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 2006; 6: 36–47.
Fitzpatrick DF, Hirschfield SL, Coffey RG . Endothelium dependent vasorelaxing activity of wine and other grape products. Am J Physiol 1993; 265: H774–H778.
Naderali EK, Smith SL, Doyle PJ, Williams G . The mechanism of resveratrol-induced vasorelaxation differs in the mesenteric resistance arteries of lean and obese rats. Clin Sci 2001; 100: 55–60.
Novakovic A, Gojkovic-Bukarica L, Peric M, Nezic D, Djukanovic B, Markovic-Lipkovski J et al. The mecanism of endothelium-independent relaxation induced by the wine polyphenol resveratrol in human internal mammary artery. J Pharmacol Sci 2006; 101: 85–90.
Chen CK, Pace-Asciak CR . Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 1996; 27: 363–366.
Naderali EK, Doyle JP, Williams G . Resveratrol induces vasorelaxation of mesenteric and uterine arteries from female guinea-pigs. Clin Sci 2000; 98: 537–543.
Rakici O, Kiziltepe U, Coskun B, Aslamaci S, Akar F . Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery. Int J Cardiol 2005; 105: 209–215.
Calderone V, Martelli A, Testai L, Martinotti E, Breschi MC . Functional contribution of the endothelial component to the vasorelaxing effects of resveratrol and NS 1619, activators of the large-conductance calcium-activated potassium channels. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 73–80.
Shin S, Jeon JH, Park D, Jang MJ, Choi JH, Choi BH et al. trans-Resveratrol relaxes the corpus cavernosum ex vivo and enhances testosterone levels and sperm quality in vivo. Arch Pharm Res 2008; 3: 83–87.
Yousif MH, Benter IF . Role of cytochrome P450 metabolites of arachidonic acid in regulation of corporal smooth muscle tone in diabetic and older rats. Vascul Pharmacol 2007; 47: 281–287.
Myung SC, Han JH, Song KK, Kang GH, Lee SY, Kim TH et al. The effects of interleukin-6 on the contraction and relaxation responses of the cavernous smooth muscle from rats. Eur J Pharmacol 2008; 589: 228–232.
El-Metwally MA, Sharabi FM, Daabees TT, Senbel AM, Mostafa T . Involvement of alpha-receptors and potassium channels in the mechanism of action of sildenafil citrate. Int J Impot Res 2007; 19: 551–557.
Takagi M, Mochida H, Noto T, Yano K, Inoue H, Ikeo T et al. Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. Eur J Pharmacol 2001; 411: 161–168.
André E, Malheiros A, Cechinel-Filho V, Yunes RA, Calixto JB . Role of nitric oxide and K+ channels in relaxation induced by polygodial in rabbit corpus cavernosum in vitro. J Cardiovasc Pharmacol 2003; 41: 300–306.
Luckhoff A, Busse R . Calcium influx into endothelial cells and formation of endothelium-derived relaxing factor is controlled by the membrane potential. Pflugers Arch 1990; 416: 305–311.
Wolfrum S, Jensen KS, Liao JK . Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729–736.
Moreland RB, Kim N, Nehra A, Goldstein I, Traish A . Functional prostaglandin E (EP) receptors in human penile corpus cavernosum. Int J Impot Res 2003; 15: 362–368.
Chen G, Suzuki H . Calcium-dependency of the endothelium-dependent hyperpolarization of vascular smooth muscle cells of the rabbit carotid artery. J Physiol 1990; 421: 521–534.
Nagao T, Vanhoutte PM . Endothelium-derived hyperpolarizing factor and endothelium-dependent relaxations. Am J Respir Cell Mol Biol 1993; 8: 1–6.
Malmsjo M, Edvinson L, Erlinge D . P2U-receptor mediated endothelium-dependent but nitric oxide independent vascular relaxation. Br J Pharmacol 1998; 123: 719–729.
Fukao M, Hattori Y, Kanno M, Sakuma I, Kitabatake A . Thapsigargin- and cyclopiazonic acid-induced endothelium-dependent hyperpolarization in rat mesenteric artery. Br J Pharmacol 1995; 115: 987–992.
Adeagbo AS, Triggle CR . Varying extracellular [K+]: a functional approach to separating EDHF- and EDNO-related mechanisms in perfused rat mesenteric arterial bed. J Cardiovasc Pharmacol 1993; 21: 423–429.
Novakovic A, Bukarica LG, Kanjuh V, Heinle H . Potassium channels-mediated vasorelaxation of rat aorta induced by resveratrol. Basic Clin Pharmacol Toxicol 2006; 99: 360–364.
Gojkovic-Bukarica L, Novakovic A, Kanjuh V, Bumbasirevic M, Lesic A, Heinle H . A role of ion channels in the endothelium-independent relaxation of rat mesenteric artery induced by resveratrol. J Pharmacol Sci 2008; 108: 124–130.
Albersen M, Shindel AW, Mwamukonda KB, Lue TF . The future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs 2010; 15: 467–480.
Liu J, Chen J . [Ion channels and penile erection]. Zhonghua Nan Ke Xue 2004; 10: 403–406, 410.
Li HF, Tian ZF, Qiu XQ, Wu JX, Zhang P, Jia ZJ . A study of mechanisms involved in vasodilatation induced by resveratrol in isolated porcine coronary artery. Physiol Res 2006; 55: 365–372.
Martínez-Piñeiro L, Galicia de PedroI, Cisneros J, Cuervo E, Frías Iniesta J, Martínez-Piñeiro JA . New features of pharmacologic treatment of erectile dysfunction. Arch Esp Urol 1996; 49: 270–276.
This study was supported by Akdeniz University Research Foundation with the 2012.01.0103.004 project number.
The authors declare no conflict of interest.
About this article
Cite this article
Dalaklioglu, S., Ozbey, G. The potent relaxant effect of resveratrol in rat corpus cavernosum and its underlying mechanisms. Int J Impot Res 25, 188–193 (2013). https://doi.org/10.1038/ijir.2013.6
- corpus cavernosum
Resveratrol reverses diabetes-related decrement in sildenafil-induced relaxation of corpus cavernosum in aged rats
Aging Clinical and Experimental Research (2017)